A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

April 14, 2023

Conditions

Necrobiosis Lipoidica

Interventions

DRUG

PCS499

PCS499 900mg twice a day with food

OTHER

placebo

placebo comparator

Trial Locations (4)

Processa Clinical Site, Charleston

Processa Clinical Site, Milwaukee

Processa Clinical Site, Rochester

Processa Clinical Site, San Diego